Long naps, a quiet warning sign of liver risk in diabetics

Introduction: an unexpected link between sleep and the liver

A simple question for a serious risk

What if a simple question about your napping habits could help your doctor spot a risk of liver disease before a single blood test is drawn? That is the hypothesis behind a new study presented on June 15, 2026 at the annual ENDO 2026 meeting of the Endocrine Society in Chicago, according to the Endocrine Society's official release.

The research establishes a link between the length of daytime naps and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), a liver condition increasingly common among people living with type 2 diabetes. The message is simple, measured, and far from sensationalist: sleeping poorly, or taking long naps, could signal an elevated risk well before any visible symptoms appear.

Why this finding deserves attention

MASLD, formerly known as non-alcoholic fatty liver disease, affects a growing share of adults worldwide, particularly those living with type 2 diabetes. This disease, often silent in its early stages, can progress to chronic liver inflammation, or even cirrhosis, if not caught in time.

What sets this study apart is its concrete proposal: use simple sleep questions as an early, accessible, and low-cost screening tool, rather than relying solely on more invasive or expensive medical tests.

The study in detail: methodology and scope

Nearly 1,900 participants followed for several years

The research team, led by Dr. Xuejiang Gu, executive director of the endocrinology department at the First Affiliated Hospital of Wenzhou Medical University in China, followed 1,900 adults aged 18 to 85, all living with type 2 diabetes, between 2017 and 2024, according to data reported by the Endocrine Society.

Sleep habits were collected via questionnaire, sorting participants into four categories: good nighttime sleep with a short nap, good nighttime sleep with a long nap, poor nighttime sleep with a short nap, and poor nighttime sleep with a long nap.

Rigorous tracking and robust statistical analysis

Researchers used a multivariate Cox regression analysis to assess the association between sleep characteristics and the onset of MASLD, with an average follow-up of just over three years per participant.

By the end of that period, 379 new cases of MASLD had been recorded among participants, a number large enough to allow statistically significant comparisons between the four sleep groups studied.

Key results: long naps as an independent risk factor

A risk that triples in the worst-case scenario

The study's central finding is unambiguous: people who take naps longer than 30 minutes every day, regardless of their nighttime sleep quality, face an elevated risk of developing MASLD. But it is the combination of both factors that worries researchers most.

According to Dr. Gu, quoted in the Endocrine Society's release: "Poor nighttime sleep combined with long naps more than triples the risk of MASLD in this population." A cautious statement, directly backed by the study's data, without exaggeration or promise of a definitive diagnosis.

The three higher-risk groups

Compared to the reference group — good nighttime sleep with a short nap — the other three sleep categories were all associated with a higher risk of MASLD. This means that neither nighttime sleep quality alone, nor nap duration alone, fully explains the risk: it is the combination of the two that matters most.

The researcher sums up the practical takeaway in accessible terms: "Our public health message for these people is to nap smart." A simple formula that avoids needless alarm while pointing to a concrete adjustment anyone can make.

Understanding MASLD: what exactly are we talking about

A quiet but fast-growing disease

Metabolic dysfunction-associated steatotic liver disease is characterized by an excessive buildup of fat in the liver, unrelated to heavy alcohol consumption. It is closely linked to obesity, insulin resistance, and, of course, type 2 diabetes, according to data compiled in a study published on PMC examining the links between sleep and liver disease.

That same study notes that people sleeping fewer than six hours a night had a 21% higher MASLD prevalence, while those sleeping more than eight hours saw that prevalence climb by 38%, illustrating a U-shaped relationship in which both sleep extremes carry elevated risk.

An underestimated public health issue

An umbrella review published in the journal Sleep Biology and Rhythms in February 2026 confirms that sleep disorders, including obstructive apnea, insomnia, and circadian misalignment, contribute to MASLD progression through several distinct biological mechanisms, including systemic inflammation and insulin resistance.

This growing body of research now places sleep among the priority modifiable targets for MASLD prevention, alongside diet and physical activity, two levers already well established in type 2 diabetes management.

Why the sleep-liver link makes biological sense

The mechanisms science suspects

Several biological pathways are being explored to explain this link. Lack of sleep or poor sleep quality disrupts hormonal regulation of metabolism, potentially increasing insulin resistance and promoting fat buildup in the liver, according to mechanisms described in a review published in the Journal of Sleep Medicine and Disorders.

Frequent snoring, for example, has been identified as an independent predictor of MASLD in several studies, with a relative risk increase of about 48%, particularly among middle-aged people, reinforcing the idea that nighttime sleep quality directly influences liver health.

The long nap, a signal rather than a direct cause

It is important to add nuance here: a long nap does not necessarily cause liver disease on its own. It could instead be a signal of insufficient or poor-quality nighttime sleep, or a symptom of chronic fatigue tied to other metabolic imbalances already present in the person.

This nuance is essential to avoid overinterpretation: the research establishes a statistical association, not proof of a direct, isolated causal link between nap duration and the onset of the disease.

What this means for diabetics in daily life

An accessible screening tool for clinicians

One of this study's most hopeful messages is how simple it is to apply clinically. Rather than requiring costly or invasive tests, a doctor could ask a few targeted questions about sleep and napping habits to quickly identify patients at elevated risk, an approach that could enable earlier and broader screening.

This approach fits within a broader trend in preventive medicine: using simple behavioral data to guide clinical decisions, not as a replacement for necessary diagnostic tests but as a way to help prioritize who should take them first.

Concrete, measured steps to remember

For people living with type 2 diabetes, the practical takeaway from this research is reasonable and accessible: aim for adequate nighttime sleep of six to eight hours, and avoid regularly taking daytime naps longer than 30 minutes.

These simple adjustments obviously do not guarantee freedom from liver disease, but they fit within a broader approach to managing type 2 diabetes that already includes diet, physical activity, and regular medical follow-up.

The study's limitations to keep in mind

A single cohort, results to be confirmed

This study, though methodologically rigorous, comes from a single institution in China and relies on self-reported questionnaire data, a recognized but inherently less reliable method compared to objective sleep measurements like polysomnography or actigraphy.

Results presented at a scientific conference, as is the case here for ENDO 2026, have generally not yet undergone full peer-reviewed publication at the time of presentation, which calls for the usual methodological caution before drawing definitive clinical conclusions.

What science cannot yet claim

It would be premature to claim that changing one's napping habits alone is enough to prevent MASLD in every diabetic person. Other factors, such as body weight, diet, physical activity, and genetics, play roles at least as significant in the development of this disease.

Scientific caution requires treating this study as one more piece of a complex puzzle, not as a definitive, standalone answer to the broader problem of MASLD among diabetics.

The bigger picture: sleep, diabetes, and metabolic health

A circle that closes in on itself

The link between disrupted sleep and metabolic problems is not limited to MASLD. Earlier research has already established an association between non-alcoholic fatty liver disease and an elevated risk of developing type 2 diabetes, suggesting a bidirectional relationship in which each condition can worsen the other over time.

This complex interaction between sleep, liver, and blood sugar shows just how much metabolic health functions as an interconnected system, where neglecting one aspect, like sleep, can ripple across multiple organs at once.

An opportunity for a more holistic approach to care

Health professionals who treat type 2 diabetes could benefit from a more integrated approach, systematically including sleep questions in their routine evaluations, rather than treating blood sugar in isolation from other aspects of patient health.

This holistic view also reflects a broader trend in preventive medicine, where behavioral factors, often overlooked in favor of pharmacological treatments, are regaining a central place in chronic disease management.

Conclusion: measured hope, not a miracle cure

A serious lead for prevention

This study, presented at ENDO 2026, offers a useful, measured contribution to our understanding of the links between sleep and liver health in diabetics. Without claiming to revolutionize medicine, it opens a concrete, accessible path to improving early screening for MASLD.

The core message remains simple and actionable: nighttime sleep quality and moderation of long naps deserve a place in conversations between diabetic patients and health professionals, alongside more traditional topics like diet and exercise.

Staying curious without giving in to exaggeration

As with any recent scientific discovery, caution is warranted: this study will need to be confirmed by other cohorts and published in full to solidify its conclusions. But it illustrates how sleep research, long underestimated, is finally earning a legitimate place in chronic metabolic disease management.

For people living with type 2 diabetes, the takeaway is reassuringly simple: sleeping better, and napping in moderation, costs nothing and could make a real difference for long-term liver health.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I sign this piece as a columnist for mad-m.ca, with no specialized medical training. My role here is to make recent scientific research accessible, honest, and measured, without ever turning a research lead into a promise of a cure or a personal diagnosis.

I am not a doctor and this article is in no way medical advice. Anyone concerned about their liver health or sleep habits should consult a qualified health professional.

My method and my sources

This article relies exclusively on the official Endocrine Society release concerning the study presented at ENDO 2026, as well as complementary studies published in peer-reviewed scientific journals, all cited in full in the Sources section below.

No data, statistic, or quote in this article was invented or extrapolated beyond what the sources allow me to state with certainty.

Sources

Primary sources

Endocrine Society, "Long naps may increase the risk of chronic liver disease in people with diabetes" — June 15, 2026

PMC, "Exploring the impact of sleep duration and sleep disorders on MASLD" — July 2, 2025

PubMed, "Relationship between metabolic dysfunction-associated steatotic liver disease and sleep disorders: an umbrella review" — February 11, 2026

Secondary sources

Journal of Sleep Medicine and Disorders, "The Interplay between Sleep Disorders and MASLD: A Mini Review" — March 13, 2025

Exploration of Digestive Diseases, "Sleep factors and metabolic dysfunction-associated steatotic liver disease" — May 22, 2026

American Diabetes Association